Company profile
CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PACMILIMAB | phase2 | — | 3 | completed, terminated |
| PRALUZATAMAB RAVTANSINE | phase2 | — | 2 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05387265 | phase1 | terminated | 2022-05-16 | 2025-06-04 | CytomX Therapeutics | A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors |
| NCT06265688 | phase1 | recruiting | 2024-04-02 | 2027-11-30 | CytomX Therapeutics | First In Human Study of CX-2051 in Advanced Solid Tumors |
| NCT06462794 | phase1 | recruiting | 2024-08-28 | 2028-02-28 | CytomX Therapeutics | First In Human Study of CX-801 in Advanced Solid Tumors |
| NCT03013491 | phase1_2 | terminated | 2017-01-19 | 2020-10-27 | CytomX Therapeutics | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas |
| NCT03706274 | phase1 | withdrawn | 2020-01-01 | 2020-12-01 | CytomX Therapeutics | PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors |
FDA applications (0)
No records yet.